Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR‐TKI treatment in advanced non‐small cell lung cancer
Author:
Affiliation:
1. Department of Respiratory Disease, Daping Hospital Army Medical University Chongqing China
2. School of Medicine Chongqing University Chongqing China
3. Burning Rock Biotech Guangzhou China
Funder
National Natural Science Foundation of China
Publisher
Wiley
Subject
Pulmonary and Respiratory Medicine,Oncology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14668
Reference33 articles.
1. Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies
2. Current progress and future perspectives of polypharmacology : From the view of non-small cell lung cancer
3. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
4. Different characteristics and survival in non‐small cell lung cancer patients with primary and acquired EGFR T790M mutation
5. The amount of activating EGFR mutations in cir‐culating cell‐free DNA is a marker to monitor osimertinib response;Re MD;Br J Cancer,2018
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations;Neoplasia;2024-07
2. A quadratic isothermal amplification fluorescent biosensor without intermediate purification for ultrasensitive detection of circulating tumor DNA;The Analyst;2024
3. Progress in the Detection of Serological Tumor Markers in Lung Cancer;Advances in Clinical Medicine;2024
4. Brief Report: Droplet Digital Polymerase Chain Reaction Versus Plasma Next-Generation Sequencing in Detecting Clearance of Plasma EGFR Mutations and Carcinoembryonic Antigen Levels as a Surrogate Measure;JTO Clinical and Research Reports;2023-12
5. Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction;Tumor Biology;2023-05-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3